10.40
-0.02(-0.19%)
Currency In USD
| Previous Close | 10.42 |
| Open | 10.21 |
| Day High | 10.49 |
| Day Low | 9.81 |
| 52-Week High | 15.47 |
| 52-Week Low | 8.06 |
| Volume | 104,248 |
| Average Volume | 69,285 |
| Market Cap | 141.75M |
| PE | -7.59 |
| EPS | -1.37 |
| Moving Average 50 Days | 11.52 |
| Moving Average 200 Days | 11.1 |
| Change | -0.02 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $2,080 as of September 29, 2025 at a share price of $10.4. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $1,098.2 as of September 29, 2025 at a share price of $10.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
GlobeNewswire Inc.
Sep 18, 2025 10:00 AM GMT
STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
GlobeNewswire Inc.
Sep 10, 2025 10:00 AM GMT
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
GlobeNewswire Inc.
Aug 20, 2025 1:25 PM GMT
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno